Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 6/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | IDE | P14735 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA9 | Q16790 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028942 | 1.00 | HLCS (0.64) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL479444 | 0.85 | HLCS (0.72) | HLCSTDP1MEN1ABL1LMNA | |
| Hydrochloric Acid SCHEMBL7374429 | 0.84 | HLCS (0.70) | HLCSTDP1MEN1ABL1LMNA | |
| Biotin SCHEMBL6033491 | 0.83 | TDP1 (0.87) | HLCSTDP1MEN1ABL1LMNA | |
| Biotin SCHEMBL8651197 | 0.83 | TDP1 (0.87) | HLCSTDP1MEN1ABL1LMNA | |
| Biotin SCHEMBL3518095 | 0.83 | TDP1 (0.87) | HLCSTDP1MEN1ABL1LMNA | |
| Biotin SCHEMBL27671459 | 0.83 | TDP1 (0.87) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL5992825 | 0.82 | HLCS (0.59) | HLCSTDP1MEN1ABL1LMNA | |
| Biotin SCHEMBL8672968 | 0.82 | TDP1 (0.85) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL20411845 | 0.81 | HLCS (0.77) | HLCSTDP1MEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584172-B2 | Chromosome biomarker | Oxford BioDynamics PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| WO-2026047046-A1 | SCREENING METHOD USING CHROMOSOMAL CONFORMATIONS FOR DETECTING COLORECTAL CANCER | Oxford BioDynamics PLC (GB) | 2026-03-05 | — | — | WO | disclosed |
| US-20260002208-A1 | CHROMOSOME INTERACTIONS | Oxford BioDynamics PLC (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20260002942-A1 | ANTI-DRUG ANTIBODY ASSAY | HOFFMANN LA ROCHE (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025215190-A1 | METHOD OF TYPING CHROMOSOME MARKERS | Oxford BioDynamics PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025215189-A1 | CHROMOSOME MARKER TEST | Oxford BioDynamics PLC (GB) | 2025-10-16 | — | — | WO | disclosed |
| US-12378315-B2 | Anti-rabbit CD19 antibodies and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4301874-B1 | CHROMOSOME INTERACTION MARKERS | Oxford BioDynamics PLC (GB) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025062136-A1 | CHROMOSOME DETECTION ASSAY | Oxford BioDynamics PLC (GB) | 2025-03-27 | — | — | WO | disclosed |
| EP-4463567-A1 | METHODS AND COMPOSITIONS FOR TRANSCRIPTOME ANALYSIS | JumpCode Genomics, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20220333199-A1 | Diagnostic Chromosome Marker | Oxford BioDynamics PLC (GB) | 2022-10-20 | — | — | US | disclosed |
| WO-2022185062-A1 | CHROMOSOME INTERACTION MARKERS | Oxford BioDynamics PLC (GB) | 2022-09-09 | — | — | WO | disclosed |
| US-20220282328-A1 | Chromosome Biomarker | Oxford BioDynamics PLC (GB) | 2022-09-08 | — | — | US | disclosed |
| US-11434522-B1 | Detection of chromosome interactions | Oxford BioDynamics PLC (GB) | 2022-09-06 | — | — | US | disclosed |
| EP-4028547-A1 | DIAGNOSTIC CHROMOSOME MARKER | Oxford BioDynamics PLC (GB) | 2022-07-20 | — | — | EP | disclosed |
| WO-2022148957-A1 | CHROMOSOME INTERACTIONS | Oxford BioDynamics PLC (GB) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148958-A1 | ANALYSIS METHOD | Oxford BioDynamics PLC (GB) | 2022-07-14 | — | — | WO | disclosed |
| US-20220135672-A1 | ANTI-RABBIT CD19 ANTIBODIES AND METHODS OF USE | HOFFMANN-LA ROCHE INC. (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2022079418-A1 | DISEASE MARKER | Oxford BioDynamics PLC (GB) | 2022-04-21 | — | — | WO | disclosed |
| EP-3966350-A1 | CHROMOSOME CONFORMATION MARKERS OF PROSTATE CANCER AND LYMPHOMA | Oxford BioDynamics PLC (GB) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002208-A1 | CHROMOSOME INTERACTIONS | MED25, RBM25, TERF2IP | HLCS 3430/4885TDP1 152/4885MEN1 2048/4885 |
| US-12584172-B2 | Chromosome biomarker | SMCHD1, SMC4, SMC3 | HLCS 3605/4885TDP1 33/4885MEN1 3761/4885 |
| US-20260002942-A1 | ANTI-DRUG ANTIBODY ASSAY | SHBG, CD2, CA13 | HLCS 249/4885TDP1 3440/4885MEN1 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.